Ceftolozane | 1B3 | Fluo-3 | 25% at 1500 µM | | | | | FDA, 2014al |
Ceritinib | 1B1 | Estradiol 17-β-glucuronide | 31.8% at 5 µM | | | | | FDA, 2014ao |
| 1B3 | Estradiol 17-β-glucuronide | 24.1% at 5 µM | | | | | |
Dapagliflozin | 1B1 | Estradiol 17-β-glucuronide | 69.3 | 0.005b | | | | FDA, 2014j |
| 1B3 | Cholecystokinin octapeptide | 8 | 0.044b | | | | |
Dasabuvir | 1B1 | N/S | 0.9 | 2.32b,c | 1.82 | 1.36 | Pravastatind | FDA, 2014ai |
| 1B3 | N/S | 6.6 | 0.32b,c | 2.59 | 7.15 | Rosuvatstatind | |
Eliglustat | 1B1 | Estrone-3-sulfate | 150 | 0.003b | | | | FDA, 2014e |
| 1B3 | Fluo-3 | 100 | 0.004b | | | | |
Empagliflozin | 1B1 | N/S | 71.8 | 0.009 | 1.00 | 0.95 | Simvastatin | FDA, 2014n |
| 1B3 | N/S | 58.6 | 0.012 | | | | |
Idelalisib | 1B1 | N/S | 10 | 0.46b,c | 1.11 | 1.21 | Rosuvastatin | FDA, 2014an |
| 1B3 | N/S | 7 | 0.66b,c | | | | |
Ledipasvir | 1B1 | Fluo-3 | 3.5 | 0.29c | | | N/T; Re < 1.25 | FDA, 2014k |
| 1B3 | Fluo-3 | 6.5 | 0.15c | | N/T; Re < 1.25 | |
Netupitant | 1B1 | Estrone-3-sulfate | 22% at 30 µM | | | | | FDA, 2014a |
| 1B3 | Fluo-3 | 44% at 30 µM | | | | | |
Olaparib | 1B1 | N/S | 20.3 | 0.9c | | | N/T; Re = 1.16 | FDA, 2014s |
| 1B3 | N/S | 25% at 100 µM | | | | | |
Paritaprevir | 1B1 | N/S | 0.031 | 61.9b,c | 1.82 | 1.36 | Pravastatind | FDA, 2014ai |
| 1B3 | N/S | 0.017 | 112.9b,c | 2.59 | 7.15 | Rosuvatstatind | |
Suvorexant | 1B1 | Pitavastatin | 48% at 10 µM | | | | | FDA, 2014c |
Tazobactam | 1B3 | Fluo-3 | 32.3% at 500 μg/ml | | | | | FDA, 2014al |
Tedizolid (phosphate) | 1B1 | Estradiol 17-β-glucuronide | 29% at 30 µMa | | | | | FDA, 2014ad |
Vorapaxar | 1B1 | Pitavastatin | 31% at 10 µM | | | | | FDA, 2014am |
| 1B3 | Bromsulphthalein | 45% at 10 µM | | | | | |